Jan van Deursen
PhD
Scientific Founder and Former Chair of Biochemistry and Molecular Biology
👥Biography 个人简介
Jan van Deursen provided the original proof-of-concept that genetic clearance of p16INK4a-positive senescent cells extends healthspan and delays cancer in the INK-ATTAC mouse model, catalyzing the entire senolytic therapy field. His BubR1 progeroid mouse studies demonstrated that senescent cell accumulation drives premature aging phenotypes including cancer susceptibility. He co-founded Unity Biotechnology to translate senolytic approaches to clinical medicine.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Jan van Deursen 的研究动态
Follow Jan van Deursen's research updates
留下邮箱，当我们发布与 Jan van Deursen（Unity Biotechnology / Mayo Clinic (former)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment